Novel Bruton’s tyrosine kinase inhibitor TAS5315 suppresses the progression of inflammation and joint destruction in rodent collagen-induced arthritis [PDF]
Rheumatoid arthritis is an inflammatory autoimmune disease, characterized by autoantibody production, synovial inflammation, and joint destruction. Its pathogenesis is due to environmental factors and genetic backgrounds.
Daichi Akasaka +9 more
doaj +3 more sources
First-Line Bruton’s Tyrosine Kinase Inhibitor-Based Regimens for Mantle Cell Lymphoma [PDF]
First-line (1L) therapy for mantle cell lymphoma (MCL) continues to evolve rapidly, with several recent phase II and phase III trials consistently showing the activity of novel covalent Bruton’s tyrosine kinase inhibitor (cBTKi) combinations.
Robert Puckrin +4 more
doaj +2 more sources
The Bruton’s Tyrosine Kinase Inhibitor Ibrutinib Impairs the Vascular Development of Zebrafish Larvae [PDF]
Ibrutinib is an orally bioavailable, irreversible selective Bruton’s tyrosine kinase inhibitor that has demonstrated impressive therapeutic effects in patients with B cell malignancies.
Kun Wang, Qiushi Xu, Hanbing Zhong
doaj +2 more sources
Development of a novel Bruton’s tyrosine kinase inhibitor that exerts anti-cancer activities potentiates response of chemotherapeutic agents in multiple myeloma stem cell-like cells [PDF]
Despite recent improvements in multiple myeloma (MM) treatment, MM remains an incurable disease and most patients experience a relapse. The major reason for myeloma recurrence is the persistent stem cell-like population.
Weam Othman Elbezanti +14 more
doaj +2 more sources
HSP90 Inhibitor Ganetespib Enhances the Sensitivity of Mantle Cell Lymphoma to Bruton’s Tyrosine Kinase Inhibitor Ibrutinib [PDF]
Mantle cell lymphoma (MCL) is a highly aggressive and heterogeneous B-cell lymphoma. Though Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib has shown great efficacy as a single agent for MCL treatment, the real-world use of ibrutinib is still subject ...
Ziwen Lu +3 more
doaj +2 more sources
Bruton’s Tyrosine Kinase Inhibitor Zanubrutinib Effectively Modulates Cancer Resistance by Inhibiting Anthracycline Metabolism and Efflux [PDF]
Zanubrutinib (ZAN) is a Bruton’s tyrosine kinase inhibitor recently approved for the treatment of some non-Hodgkin lymphomas. In clinical trials, ZAN is often combined with standard anthracycline (ANT) chemotherapy. Although ANTs are generally effective,
Lucie Čermáková +6 more
doaj +2 more sources
P1603: EFFICACY AND SAFETY OF BRUTON’S TYROSINE KINASE INHIBITOR ZANUBRUTINIB IN ITP [PDF]
Qiu-Sha Huang +9 more
doaj +2 more sources
PB2381: EFFICACY ANALYSIS OF BRUTON’S TYROSINE KINASE INHIBITOR COMBINED REGIMEN IN THE TREATMENT OF ELDERLY PATIENTS WITH RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA [PDF]
Wenyu Shi
doaj +2 more sources
P1005: EFFECT OF TL-895, A NOVEL BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ON ONCOGENIC JANUS KINASE 2-V617F (JAK2VF) SIGNALING [PDF]
Subbaiah Chary Nimmagadda +7 more
doaj +2 more sources
Novel Bruton’s Tyrosine Kinase inhibitor remibrutinib: Drug‐drug interaction potential as a victim of CYP3A4 inhibitors based on clinical data and PBPK modeling [PDF]
Remibrutinib, a novel oral Bruton’s Tyrosine Kinase inhibitor (BTKi) is highly selective for BTK, potentially mitigating the side effects of other BTKis. Enzyme phenotyping identified CYP3A4 to be the predominant elimination pathway of remibrutinib.
Felix Huth +8 more
doaj +2 more sources

